# AGAP3

## Overview
AGAP3 is a gene that encodes the protein ArfGAP with GTPase domain, ankyrin repeat, and PH domain 3, which is involved in various cellular processes, particularly in the nervous system. This protein is categorized as a multifunctional signaling molecule due to its diverse domains, including a GTPase-like domain, a pleckstrin homology (PH) domain, an ArfGAP domain, and ankyrin repeats. These domains enable AGAP3 to participate in the regulation of AMPA receptor trafficking and synaptic plasticity, which are critical for learning and memory (Oku2013AGAP3). AGAP3 is predominantly localized at postsynaptic sites in the brain, where it interacts with components of the NMDA receptor complex, linking NMDA receptor activation to AMPA receptor trafficking (Oku2013AGAP3). Additionally, AGAP3 has been implicated in various diseases, including acute myeloid leukemia and Erdheim-Chester Disease, through its involvement in cellular signaling pathways and genetic fusions (Nishino2024Pulmonary; Desai2023Whole).

## Structure
AGAP3 is a multi-domain protein characterized by the presence of several specific domains, including a GTPase-like domain, a pleckstrin homology (PH) domain, an ArfGAP domain, and ankyrin repeats. It also features a putative type-I PDZ ligand at its extreme C terminus (Oku2013AGAP3). These domains suggest that AGAP3 has bifunctional enzymatic activities, with the GTPase domain involved in activity-dependent AMPA receptor trafficking and the ArfGAP domain inhibiting ARF6, a regulator of endocytosis (Højgaard2023Noveltyinduced).

AGAP3 exists in multiple splice variants, including a full-length 98 kDa protein, a 58 kDa protein, and a 43 kDa protein known as CRAG (CRMP-5-associated GTPase). These variants suggest different physiological functions, as the multidomain structure of AGAP3 is split among them (Oku2013AGAP3). The CRAG variant, which contains only the N-terminal GTPase-like domain, is important for axon guidance and protection from oxidative stress during neuronal development (Højgaard2023Noveltyinduced).

AGAP3 is found at postsynaptic sites in the adult brain, with expression peaking at postnatal days 7-15 and continuing into adulthood. It is enriched in postsynaptic density fractions, indicating its postsynaptic localization (Oku2013AGAP3). The protein may undergo post-translational modifications like phosphorylation, influencing its function and interactions. However, specific details on the primary, secondary, tertiary, or quaternary structure of AGAP3 are not provided in the available context.

## Function
AGAP3 is a protein that plays a critical role in the regulation of AMPA receptor trafficking and synaptic plasticity in neurons. It is a component of the NMDA receptor signaling complex and is involved in both basal and activity-dependent signaling pathways. AGAP3 regulates the trafficking of GluA1, a subunit of AMPA receptors, during chemical long-term potentiation (cLTP), a process important for synaptic plasticity. The protein influences Ras/ERK and Arf6 signaling pathways, which are essential for AMPA receptor trafficking (Oku2013AGAP3).

AGAP3 contains multiple signaling domains, including a GTPase-like domain, a pleckstrin homology domain, and an ArfGAP domain. The ArfGAP domain is specifically involved in basal trafficking of AMPA receptors, while the GTPase domain regulates Ras/ERK signaling, crucial for activity-dependent trafficking. Knockdown of AGAP3 leads to increased basal surface levels of AMPA receptors and affects Ras and Arf6 activity (Oku2013AGAP3).

AGAP3 is primarily localized at postsynaptic sites in the brain, as indicated by its overlap with the postsynaptic marker PSD95. This localization suggests that AGAP3 plays a significant role in synaptic function and plasticity, contributing to learning and memory processes (Oku2013AGAP3).

## Clinical Significance
AGAP3 has been implicated in various diseases and conditions due to its role in cellular signaling pathways. In acute myeloid leukemia (AML), a novel fusion transcript involving AGAP3, known as HOXD11-AGAP3, has been identified in an Indian cohort. This fusion is associated with specific cytogenetic abnormalities and alterations in immune system pathways, suggesting a potential role in leukemogenesis (Desai2023Whole). The expression of AGAP3 is upregulated in acute leukemia samples compared to normal blood samples, indicating a possible population-specific expression pattern that may influence disease progression and patient survival (Desai2023Whole).

In Erdheim-Chester Disease (ECD), a rare inflammatory myeloid neoplasm, a BRAF-AGAP3 fusion has been identified. This fusion is rare and was associated with late-onset osteolytic bone lesions in a patient, which responded to treatment with trametinib, a MEK inhibitor. The case highlights the importance of genetic testing in ECD and suggests that the BRAF-AGAP3 fusion may be sensitive to corticosteroid treatment (Nishino2024Pulmonary).

AGAP3 has also been studied in the context of neurological disorders, where its role in synaptic plasticity and receptor trafficking is crucial. However, specific diseases directly linked to AGAP3 mutations or dysregulation in neurological contexts are not detailed in the provided sources.

## Interactions
AGAP3 interacts with SynGAP, a component of the NMDA receptor complex, through its RasGAP domain. This interaction was identified using a yeast two-hybrid screen and confirmed by coimmunoprecipitation experiments in HEK293T cells, indicating a direct interaction. AGAP3's GTPase activity is regulated by SynGAP, as demonstrated by an increase in AGAP3 GTPase activity upon the addition of SynGAP's RasGAP domain (Oku2013AGAP3).

AGAP3 is part of the NMDA receptor complex and preferentially binds to the NR2A subunit over the NR2B subunit, suggesting subunit-specific signaling. This interaction links NMDA receptor activation to AMPA receptor trafficking, which is crucial for synaptic plasticity, learning, and memory (Oku2013AGAP3). AGAP3 coimmunoprecipitates with the NR2A subunit, indicating a physical interaction, but does not coimmunoprecipitate with the NR2B subunit (Oku2013AGAP3).

AGAP3 also interacts with Arf6, acting as a GTPase-activating protein (GAP) for Arf6. This interaction is important for regulating AMPA receptor trafficking, as evidenced by increased surface GluA1 levels upon AGAP3 knockdown. Dominant-negative Arf6 can block the effects of AGAP3 knockdown on GluA1 trafficking, further supporting this interaction (Oku2013AGAP3).


## References


[1. (Nishino2024Pulmonary) Koichi Nishino, Tatsuya Takagi, Takuo Hayashi, Shinya Kunimine, Hitoshi Tsuchihashi, Shunsuke Kato, Kazuhisa Takahashi, and Kuniaki Seyama. Pulmonary erdheim-chester disease with braf-agap3 fusion: late-onset osteolytic femoral lesions despite long-term pulmonary stabilization with corticosteroid. Cureus, March 2024. URL: http://dx.doi.org/10.7759/cureus.55670, doi:10.7759/cureus.55670. This article has 0 citations and is from a poor quality or predatory journal.](https://doi.org/10.7759/cureus.55670)

[2. (Oku2013AGAP3) Y. Oku and R. L. Huganir. Agap3 and arf6 regulate trafficking of ampa receptors and synaptic plasticity. Journal of Neuroscience, 33(31):12586–12598, July 2013. URL: http://dx.doi.org/10.1523/JNEUROSCI.0341-13.2013, doi:10.1523/jneurosci.0341-13.2013. This article has 70 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1523/JNEUROSCI.0341-13.2013)

[3. (Højgaard2023Noveltyinduced) Kristoffer Højgaard, Bianka Szöllősi, Kim Henningsen, Natsumi Minami, Nobuhiro Nakanishi, Erik Kaadt, Makoto Tamura, Richard G.M. Morris, Tomonori Takeuchi, and Betina Elfving. Novelty-induced memory consolidation is accompanied by increased agap3 transcription: a cross-species study. Molecular Brain, September 2023. URL: http://dx.doi.org/10.1186/s13041-023-01056-4, doi:10.1186/s13041-023-01056-4. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13041-023-01056-4)

[4. (Desai2023Whole) Sagar Sanjiv Desai, Febina Ravindran, Amey Panchal, Nishit Ojha, Sachin Jadhav, and Bibha Choudhary. Whole transcriptome sequencing reveals hoxd11-agap3, a novel fusion transcript in the indian acute leukemia cohort. Frontiers in Genetics, April 2023. URL: http://dx.doi.org/10.3389/fgene.2023.1100587, doi:10.3389/fgene.2023.1100587. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2023.1100587)